Editorial
|
|
|
|
|
A patient group raises awareness about Lyell and Stevens-Johnson syndromes
|
|
|
|
Marketing Authorisations
|
|
|
|
|
After hip or knee replacement: LMWH remains the standard treatment
|
|
|
|
|
|
|
|
|
|
|
|
No better than a bisphosphonate
|
|
|
|
|
|
|
|
|
|
|
|
Too many outstanding questions
|
|
|
|
|
|
|
|
|
|
|
|
Is a combination with topiramate on the horizon?
|
|
|
|
Adverse Effects
|
|
|
|
|
Mostly at initiation of therapy
|
|
|
|
|
|
|
|
|
|
Acarbose and miglitol should not be used
|
|
|
|
|
|
|
|
|
|
The imipenem + cilastatin combination is safer
|
|
|
|
|
|
|
|
|
|
Increased doubts about its harm-benefit balance
|
|
|
|
|
|
|
|
|
|
Disproportionate adverse effects
|
|
|
|
|
|
|
|
|
|
Wrong route of administration
|
|
|
|
Reviews
|
|
|
|
|
Too many adverse effects
|
|
|
|
|
|
|
|
|
|
Still endemic in some parts of the world
|
|
|
|
|
|
Outlook
|
|
|
|
|
Challenging the "risk-benefit ratio"
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
European regulation is inadequate
|
|
|
|
|
|